424 related articles for article (PubMed ID: 19543771)
1. Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysis.
Santillan AA; Delman KA; Beasley GM; Mosca PJ; Hochwald SN; Grobmyer SR; Andtbacka RH; Noyes RD; Kane JM; Ross MI; Tyler DS; Zager JS
Ann Surg Oncol; 2009 Sep; 16(9):2570-8. PubMed ID: 19543771
[TBL] [Abstract][Full Text] [Related]
2. Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients.
Kroon HM; Moncrieff M; Kam PC; Thompson JF
Ann Surg Oncol; 2009 May; 16(5):1184-92. PubMed ID: 19224289
[TBL] [Abstract][Full Text] [Related]
3. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US.
Beasley GM; Caudle A; Petersen RP; McMahon NS; Padussis J; Mosca PJ; Zager JS; Hochwald SN; Grobmyer SR; Delman KA; Andtbacka RH; Noyes RD; Kane JM; Seigler H; Pruitt SK; Ross MI; Tyler DS
J Am Coll Surg; 2009 May; 208(5):706-15; discussion 715-7. PubMed ID: 19476821
[TBL] [Abstract][Full Text] [Related]
4. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB
Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of repeat isolated limb infusion with melphalan and actinomycin D for recurrent melanoma.
Kroon HM; Lin DY; Kam PC; Thompson JF
Cancer; 2009 May; 115(9):1932-40. PubMed ID: 19288571
[TBL] [Abstract][Full Text] [Related]
6. Outcomes following isolated limb infusion for melanoma. A 14-year experience.
Kroon HM; Moncrieff M; Kam PC; Thompson JF
Ann Surg Oncol; 2008 Nov; 15(11):3003-13. PubMed ID: 18509706
[TBL] [Abstract][Full Text] [Related]
7. Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion.
Beasley GM; Petersen RP; Yoo J; McMahon N; Aloia T; Petros W; Sanders G; Cheng TY; Pruitt SK; Seigler H; Tyler DS
Ann Surg Oncol; 2008 Aug; 15(8):2195-205. PubMed ID: 18528730
[TBL] [Abstract][Full Text] [Related]
8. Is melphalan dose adjustment according to ideal body weight useful in isolated limb infusion for melanoma?
Huismans AM; Kroon HM; Haydu LE; Kam PC; Thompson JF
Ann Surg Oncol; 2012 Sep; 19(9):3050-6. PubMed ID: 22526898
[TBL] [Abstract][Full Text] [Related]
9. Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs.
Klop WM; Vrouenraets BC; van Geel BN; Eggermont AM; Klaase JM; Nieweg OE; Kroon BB
J Am Coll Surg; 1996 Jun; 182(6):467-72. PubMed ID: 8646345
[TBL] [Abstract][Full Text] [Related]
10. Isolated limb infusion for malignant melanoma: predictors of response and outcome.
Barbour AP; Thomas J; Suffolk J; Beller E; Smithers BM
Ann Surg Oncol; 2009 Dec; 16(12):3463-72. PubMed ID: 19830498
[TBL] [Abstract][Full Text] [Related]
11. Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusion.
Noorda EM; Vrouenraets BC; Nieweg OE; van Geel AN; Eggermont AM; Kroon BB
Eur J Surg Oncol; 2006 Apr; 32(3):318-24. PubMed ID: 16412605
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of isolated limb infusion with cytotoxic drugs in elderly patients with advanced locoregional melanoma.
Kroon HM; Lin DY; Kam PC; Thompson JF
Ann Surg; 2009 Jun; 249(6):1008-13. PubMed ID: 19474677
[TBL] [Abstract][Full Text] [Related]
13. Isolated limb infusion for advanced soft tissue sarcoma of the extremity.
Moncrieff MD; Kroon HM; Kam PC; Stalley PD; Scolyer RA; Thompson JF
Ann Surg Oncol; 2008 Oct; 15(10):2749-56. PubMed ID: 18648882
[TBL] [Abstract][Full Text] [Related]
14. A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity.
Brady MS; Brown K; Patel A; Fisher C; Marx W
Ann Surg Oncol; 2006 Aug; 13(8):1123-9. PubMed ID: 16791448
[TBL] [Abstract][Full Text] [Related]
15. Australian multi-center experience outside of the Sydney Melanoma Unit of isolated limb infusion chemotherapy for melanoma.
Coventry BJ; Kroon HM; Giles MH; Henderson M; Speakman D; Wall M; Barbour A; Serpell J; Paddle P; Coventry AG; Sullivan T; Smithers BM
J Surg Oncol; 2014 Jun; 109(8):780-5. PubMed ID: 24634160
[TBL] [Abstract][Full Text] [Related]
16. Microdialysis and response during regional chemotherapy by isolated limb infusion of melphalan for limb malignancies.
Thompson JF; Siebert GA; Anissimov YG; Smithers BM; Doubrovsky A; Anderson CD; Roberts MS
Br J Cancer; 2001 Jul; 85(2):157-65. PubMed ID: 11461070
[TBL] [Abstract][Full Text] [Related]
17. Isolated limb perfusion for unresectable melanoma of the extremities.
Noorda EM; Vrouenraets BC; Nieweg OE; van Geel BN; Eggermont AM; Kroon BB
Arch Surg; 2004 Nov; 139(11):1237-42. PubMed ID: 15545572
[TBL] [Abstract][Full Text] [Related]
18. Maximizing efficacy and minimizing toxicity in isolated limb perfusion for melanoma.
Thompson JF; Lai DT; Ingvar C; Kam PC
Melanoma Res; 1994 Mar; 4 Suppl 1():45-50. PubMed ID: 8038596
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure.
Grünhagen DJ; van Etten B; Brunstein F; Graveland WJ; van Geel AN; de Wilt JH; Eggermont AM
Ann Surg Oncol; 2005 Aug; 12(8):609-15. PubMed ID: 15968498
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan.
Klaase JM; Kroon BB; van Geel AN; Eggermont AM; Franklin HR; Hart AA
Surgery; 1994 Jan; 115(1):39-45. PubMed ID: 8284759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
